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Abstract
One of the major risk factors for global death and disability is alcohol, tobacco, and
illicit drug use. While there is increasing knowledge with respect to individual factors
promoting the initiation and maintenance of substance use disorders (SUDs), disease
trajectories involved in losing and regaining control over drug intake (ReCoDe) are
still not well described. Our newly formed German Collaborative Research Centre
(CRC) on ReCoDe has an interdisciplinary approach funded by the German Research
Foundation (DFG) with a 12-year perspective. The main goals of our research consor-
tium are (i) to identify triggers and modifying factors that longitudinally modulate the
trajectories of losing and regaining control over drug consumption in real life, (ii) to
study underlying behavioral, cognitive, and neurobiological mechanisms, and (iii) to
implicate mechanism-based interventions. These goals will be achieved by: (i) using
mobile health (m-health) tools to longitudinally monitor the effects of triggers (drug
cues, stressors, and priming doses) and modify factors (eg, age, gender, physical activ-
ity, and cognitive control) on drug consumption patterns in real-life conditions and in
animal models of addiction; (ii) the identification and computational modeling of key
mechanisms mediating the effects of such triggers and modifying factors on goal-
directed, habitual, and compulsive aspects of behavior from human studies and ani-
mal models; and (iii) developing and testing interventions that specifically target the
underlying mechanisms for regaining control over drug intake.
K E YWORD S
addiction, alternative rewards, animal and computational models, cognitive-behavioral control,
craving and relapse, habit formation
1 | INTRODUCTION
We established a collaborative research center (CRC) in mid-2019,
which brings together scientists with complementary expertise in
addiction research from three internationally recognized centers
(Charité Berlin, Technical University of Dresden, and Central Institute
of Mental Health in Mannheim) in Germany. Our multidisciplinary Los-
ing and Regaining Control over Drug Intake (ReCoDe) consortium con-
sists of 40 principal investigators (PIs) and it will be substantially
funded for up to 12 years (three 4-year funding periods) by the
German Research Foundation (DFG). The consortium integrates a
range of fields, including psychology, medicine, computation and
machine learning, and neurobiology, allowing experts (for clinical and
animal studies) to move basic science discoveries into practice.
2 | KEY AIMS AND RESEARCH DOMAINS
OF THE RECODE CONSORTIUM
The main goals of our research consortium are (a) to identify triggers
and modifying factors that longitudinally modulate the trajectories of
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losing and regaining control over drug consumption in real life
(Research Domain A), (b) to study underlying behavioral, cognitive,
and neurobiological mechanisms (Research Domain B), and (c) to
develop mechanism-based interventions (Research Domain C)
(Figure 1).
We build a work plan and design the methodology to investigate
the following core research domains:
1. Domain A: Defining individual trajectories of ReCoDe requires a
holistic approach, which longitudinally assesses the interactions
between triggers (drug cues, stressors, and priming doses) and
modifying factors (eg, age, gender, physical activity, and cognitive
functions) in real life in substance use disorder (SUD) subjects and
in animal models of addiction. Technically, we will use mobile
health (m-health) tools such as individual assessment devices fitted
with mobile sensors (wearables) and accelerometers. The former
technology will acquire geolocation and additional data on psycho-
logical and physiological cue and stress reactivity and on alcohol
intake, while the latter will collect intensive longitudinal datasets
(ILDs). These data will be combined with app-based tests for key
cognitive control and learning mechanisms in real-life settings. We
will analyze the data using new multiscale analysis tools from sta-
tistical physics and biosignal processing to identify tipping points
in substance use trajectories.
2. Domain B: The effects of the above-mentioned triggers and modi-
fying factors on goal-directed, habitual, and compulsive aspects of
addictive behaviors are mediated by distinct processes (eg, cue
reactivity, habitization, reduced choice of alternative rewards, and
reduced cognitive control). Here, we will build computational
models by using animal and human data. The goal of our models
are to understand the corticolimbic control mechanisms as well as
aberrant learning mechanisms and their interaction with triggers
and modifying factors, which bias behavior towards drug seeking
and intake.
3. Domain C: Based on the prediction of individual trajectories of los-
ing and regaining control, we will develop mechanism-based
interventions that specifically match the above-mentioned key
processes (eg, cue reactivity, habitization, reduced choice of alter-
native rewards, and reduced cognitive control).
3 | RESEARCH DOMAIN A: DESCRIPTION
OF ANTECEDENTS AND TRAJECTORIES OF
LOSING AND REGAINING CONTROL AND
MODULATING FACTORS
The first goal of this joint research effort is to identify triggers and
modifying factors that longitudinally modulate the trajectories of los-
ing and regaining control over drug consumption in real life across the
lifespan.
Losing control over drug intake is a gradual and dimensional pro-
cess, which starts with goal-directed drug intake and proceeds to
habitual and ultimately compulsive drug use. Interestingly, a limited
number of addicted subjects manage to regain behavioral control over
compulsive drug intake without professional help, either by becoming
abstinent (up to 19% of untreated alcohol-dependent patients) or by
substantially reducing drug intake, for example, by decreasing tobacco
or alcohol consumption.1-4 Even in patients with severe stages of
alcohol dependence who require detoxification, a few percent manage
to drink small amounts of alcohol for a longer period of time without
again losing control.5 Regaining behavioral control over drug intake
has been attributed to mindful selection of goals replacing habitual
behavior, extinction of drug cue-induced behavioral tendencies, regu-
lation of drug craving and prioritization of alternative nondrug
rewards, and increased cognitive control over behavior including
inhibitory control.3,6-8
In Domain A of our CRC, we will identify common, as well as age-
and gender-specific factors that contribute to losing and regaining
control over consumption of alcohol (and other drugs of abuse), by a
systematic longitudinal assessment of a large sample of persons with
mild to moderate alcohol use disorder (AUD), who do not (yet) require
detoxification. This traditional longitudinal cohort study approach
F IGURE 1 The losing and regaining control over drug intake (ReCoDe) framework to study losing and regaining control over drug intake over
a 12-year perspective: Our 19 projects are divided into three research domains. Research domain A relates to trajectories of alcohol and drug
intake. Research domain B relates to mechanisms (eg, cue reactivity) on different system levels (behavioral, neural, and molecular) and research
domain C focusses on the modification of mechanisms (eg, by increasing cognitive control via physical activity or neurofeedback)
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using latent growth curve and growth mixture models9 will be com-
bined with in-depth ambulatory assessments several times a week.
We will use Ambulatory Assessment including Ecological Momentary
Assessment (EMA)10 to acquire ILDs over several months in AUD
patients with and without additional tobacco and cannabis use. For
EMA, we will use smartphones with additional mobile sensors (wear-
ables) which will be used to measure physical activity, data on location
(GPS), geolocation-based triggering of e-diaries, self-reported stress
reactivity, cue exposure (encounter with drug-related stimuli in real
life), drug craving, impulsivity, and drug consumption (priming doses,
binges, and continuous use of all drugs of abuse). App-based brief
questionnaires and cognitive11 tasks that allow the assessment of
momentary emotional, motivational, and cognitive states, including
new brief games to assess Pavlovian and instrumental (model-based
and model-free) learning mechanisms as well as sensors to detect
physiological stress responses will be applied (Figure 2).
The ILDs will undergo multiscale statistical analysis to identify
early warning signs and critical phases12 indicative for craving and
drug use as reported online and as assessed in animal models of addic-
tion. ILDs will also be collected to acquire predictive models of single
subjects and their behavioral dynamics, using cutting-edge AI tech-
niques like deep recurrent neural networks.13 The influence of age
and gender, as well as adverse life events on the occurrence of early
warning signs and critical phases, will be studied in humans and in
related animal experiments. DSM-IV/5-based animal models of
addictive-like behavior14,15 will be run in parallel for sampling ILDs
and for running modulating factors under more controlled conditions.
Such translational animal models will be also key to studying neurobi-
ological and molecular mechanisms underlying loss of control (Domain
B) and new interventions (Domain C).
To take into account the variance explained by genetic factors
which ranges between 40% and 70% for the different SUDs,16 as well
as epigenetic factors, biomaterial will be assessed from all participants
at all time points. In an innovative approach, the data from genome-
and epigenome-wide analyses will be integrated into the computa-
tional models mentioned above.
4 | RESEARCH DOMAIN B: BEHAVIORAL
AND COGNITIVE CONTROL MECHANISMS
AND THEIR MOLECULAR/
NEUROBIOLOGICAL CORRELATES
UNDERLYING LOSING AND REGAINING
CONTROL
The second goal is to identify and to computationally model key
mechanisms mediating the effects of such triggers and modifying fac-
tors on goal-directed, habitual, and compulsive aspects of behavior in
corresponding human studies and animal experiments. In Domain B,
F IGURE 2 We will acquire a highly phenotyped cohort of female and male subjects with substance use disorder (SUD) (N = 900 patients plus
150 age-matched controls) focusing on alcohol use but allowing comorbidity with other drugs of abuse. Subjects with SUD will use apps and
handheld devices for Ecological Momentary Assessment (EMA) including accelerometers to measure physical activity. Stress and drug exposure,
supportive social encounters, and trajectories of increasing or decreasing drug intake, as well as binging, will regularly be monitored over the
observation time of one year (sparse sampling). Multi-modal neuroimaging will be acquired at months 3 and 9. For in-depth assessment of
cognitive control, we will use additional apps to assess working memory and other executive functions in real life with respect to drug intake ort.
In addition, we will assess stress reactivity profiles and explore their interaction with trajectories of craving and alcohol intake. Besides this sparse
data sampling approach, we will use specialized apps for intensive EMA to collect e-Diaries, sensor, and geolocation data in subjects at course
transition points, ie, with substantial increases and decreases of alcohol intake (intense sampling). This intensive data sampling will provide
detailed information on momentary effects of triggers on subjective craving, mood, impulsivity, physiological responses, and alcohol consumption
in real-world settings, identify their neural correlates, and test the predictive value of the identified mechanisms for subsequent course
trajectories. Finally, data integration and postprocessing will yield early warning signs and tipping points in drug consumption and will allow us to
computational model trajectories of alcohol consumption
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the impact of triggers and modulating factors on the proposed learn-
ing and control mechanisms in subjects with AUD deriving from our
longitudinal real-life assessment (such as stress, cue exposure, and
physical activity) will be assessed in laboratory experiments and com-
pared with tobacco use disorder (TUD) in order to achieve generaliz-
ability of our conclusions. Closely linked human studies and animal
experiments will assess key learning and control mechanisms and
measure their neurobiological and molecular correlates that contribute
to a shift from goal-directed to habitual and ultimately compulsive
drug consumption and their potential readjustment when regaining
goal-directed control. In particular, we will examine and build compu-
tational models for specific learning mechanisms, such as Pavlovian
mechanisms including Pavlovian-to-instrumental transfer (PIT) that
energizes ongoing drug-seeking, for goal-directed vs habitual decision
making and for corticolimbic control mechanisms of craving and
behavior and their respective effects on prospective drug intake.
5 | RESEARCH DOMAIN C: SPECIFIC
INTERVENTIONS FOR REGAINING CONTROL
The third aim is to develop and test interventions that specifically tar-
get the underlying mechanisms for regaining control over drug intake.
Domain C focuses on the modification of learning and cognitive con-
trol mechanisms in subjects with SUD. In the first 4-year funding
period, the interventions will begin by examining the modification of
learning processes and the effects of physical exercise on cognitive
control. In particular, we will use (a) cognitive remediation treatment
and implicit computer-based habit-modifying training aiming at habit-
ual vs goal-directed control of behavior. (b) We will focus on modify-
ing Pavlovian and instrumental learning parameters by specific
alterations of Pavlovian cue value and general stress reduction tech-
niques. (c) We will measure effects of physical exercise training on
working memory and craving regulation and their respective impact
on drug intake, and (iv) we will use neurofeedback to modulate key
brain areas associated with cue-reactivity and control over drug
intake.17
In a 12-year perspective, we will assess cognitive, emotional, and
behavioral trainings as well as neurobiological interventions such as
brain stimulation or specific pharmacological therapies addressing
mechanisms identified in Domains A and B. To do so, Domain C will
use information on risk and protective factors from Domain A
observed under real-life conditions, as well as the learning and execu-
tive control paradigms from Domain B and their computational model-
ing. Domain C will thus increasingly be able to identify the most
efficient intervention strategies to strengthen control mechanisms
and to alter aberrant learning mechanisms. This will result in specific
mechanism-based intervention strategies for alcohol-dependent
patients and patients suffering from other addictions.
5.1 | Summary and outlook
Here, we suggest a set of approaches in addiction research which can
promote understanding the mechanisms underlying losing versus
regaining control over drug intake. Specifically, a dimensional
approach can help to facilitate long-term assessment of subjects with
mild to moderate AUD who do not need to be detoxified. Among
these subjects with AUD, technical advances in m-health tools such as
EMA, GPS-based geolocation, and mobile sensors allow monitoring of
behavior, cognitive-emotional states, stress reactivity, and environ-
mental exposures under real-life conditions. Computational and AI-
based models can then be applied to these data in order to identify
key computational steps in goal-directed and habitual decision-making
and their neurobiological correlates in reward-related learning, stress-
reactivity, and cognitive control.
A long-term aim of our ReCoDe consortium is to amend impaired
control or even loss of control and thereby to reduce drug seeking
and intake by identifying common and specific cognitive and neurobi-
ological mechanisms and by probing specific interventions for addic-
tive behavior in men and women across the lifespan. Synergistic
effects and added value will be achieved by using translational animal
models, applying the same learning paradigms and computational
models in animal experiments and human studies, and by building tan-
dem projects between basic and clinical addiction researchers to maxi-
mize the translational nature of this work. Clinical relevance will be
ensured by using a complementary set of approaches, from computa-
tional modeling, to tightly coordinated animal experiments and human
studies, to pilot testing interventions. In a 12-year perspective, our
ReCoDe initiative will assess cognitive, emotional, and behavioral
trainings, as well as neurobiological interventions such as brain stimu-
lation or specific pharmacological therapies addressing mechanisms
identified in Domains A and B, working towards the ultimate goal of
developing mechanism-based individualized treatments.
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